Peter Zdziarski: Gene Therapy vs Prophylaxis in Glanzmann Thrombasthenia
Peter Zdziarski, Vice President and Marketing Director at the Glanzmann’s Research Foundation, shared a post on LinkedIn:
”Gene Therapy vs Prophylaxis in Glanzmann Thrombasthenia
This is one of the most frequently asked questions I hear from the GT community, and it’s a crucial one.
The distinction matters:
Prophylaxis requires ongoing drug use, often weekly or bi-weekly.
Gene therapy is designed as a single procedure and has the potential for a lasting solution.
What’s important to remember is that both options are still in clinical trials. Marketing to the GT community has put a heavy spotlight on prophylaxis in recent years. For many families, this has made it seem like the only new option, when in fact gene therapy for GT has been in development for years.
That’s why staying informed is so critical. There is meaningful research happening that could change the future of treatment. Both options, and the realities behind them, deserve attention.
If you or a loved one is living with GT, I strongly encourage you to follow the groundbreaking work of Dr. David Wilcox and his team at the Medical College of Wisconsin. Their efforts are bringing real hope for a long-term solution to Glanzmann Thrombasthenia.
Knowledge is power. The more we understand the science, the costs, and the possibilities, the better prepared we are to make the best decisions for our community’s future.”
Find more information here.
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 6, 2026, 16:43Beth Shirley: Xylitol Consumption Increases Platelet Reactivity and Cardiovascular Risk
-
Oct 6, 2026, 16:37Jared Rice: What Sets the Transfusion Threshold in Anemia of Prematurity?
-
Oct 6, 2026, 16:30Thirunavukkarasu Angappan: Immunoglobulin Decides How Much Plasma Gets Collected
-
Oct 6, 2026, 16:18Gemma Davies: New CMML Research Selected for Presentation at the 68th ASH Annual Meeting
-
Oct 6, 2026, 16:03Professor Csongor Kiss Receives the Kálmán Laki Prize – Hungarian Society of Thrombosis and Haemostasis
-
Oct 6, 2026, 15:52Mark Kheifets: A Massive Stent Thrombosis Requiring Aspiration Thrombectomy
-
Oct 6, 2026, 15:40Joseph Aslan։ Targeting Mitochondrial Permeability Transition To Reduce Platelet Thrombogenicity
-
Oct 6, 2026, 15:36Nominations Open for ISTH Outstanding Mentor Awards – ISTH
-
Oct 6, 2026, 15:17Walaa Obaid: How Warfarin Went From Poison To Medicine